Skip to main content

Table 3 Baseline characteristics of clinical trials in primary and secondary endpoints

From: Clinical outcomes meta-analysis: measuring subendocardial perfusion and efficacy of transmyocardial laser revascularization with nuclear imaging

 

Control (%)

Treatment (%)

p value

no. studies

Demographics

 Female

29.5

29.6

0.92

14

 Mean age

62.1

61.8

0.32

13

Medical History

 CABG

66.7

66.9

0.37

14

 PTCA

31.5

29.4

0.49

12

 Acute MI

62.7

62.8

0.95

15

 CHF

21.6

20.5

0.74

7

Cardiac Status

 Mean LVEF

49.4

49.5

0.95

11

 NYHA Class III

55.6

52.6

0.19

8

 NYHA Class IV

44.4

47.4

0.19

8

 Unstable angina

9.0

24.2

<0.01

5

Risk Factors

 HTN

64.5

62.9

0.55

9

 Hypercholesterolemia/HLD

80.6

73.2

0.01

5

 DM

36.8

35.7

0.65

13

 Tobacco use

31.4

30.6

0.56

11

  1. control = MM and CABG treatment = TMR and CABG/TMR